Samjin Pharmaceuticals Co., Ltd. (KRX:005500)
South Korea flag South Korea · Delayed Price · Currency is KRW
19,340
+70 (0.36%)
At close: Oct 2, 2025
0.36%
Market Cap237.07B
Revenue (ttm)274.03B
Net Income (ttm)21.89B
Shares Out12.26M
EPS (ttm)1,727.82
PE Ratio11.19
Forward PE10.49
Dividend800.00 (4.14%)
Ex-Dividend DateDec 27, 2024
Volume16,444
Average Volume55,101
Open19,240
Previous Close19,270
Day's Range19,170 - 19,490
52-Week Range16,590 - 21,300
Beta0.20
RSI48.67
Earnings DateNov 14, 2025

About Samjin Pharmaceuticals

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clin... [Read more]

Sector Healthcare
Founded 1968
Employees 586
Stock Exchange Korea Stock Exchange
Ticker Symbol 005500
Full Company Profile

Financial Performance

In 2022, Samjin Pharmaceuticals's revenue was 274.03 billion, an increase of 9.58% compared to the previous year's 250.07 billion. Earnings were 21.89 billion, a decrease of -22.92%.

Financial Statements

News

There is no news available yet.